#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 3

#### VERTEX PHARMACEUTICALS INC / MA

Form 3

January 25, 2006

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 

3235-0104 Number:

**OMB APPROVAL** 

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Statement

(Month/Day/Year)

01/25/2006

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Altus Pharmaceuticals Inc. [ALTU]

 VERTEX PHARMACEUTICALS INC /

MA

(Last)

(First) (Middle) 4. Relationship of Reporting Person(s) to Issuer

Director

5. If Amendment, Date Original

Filed(Month/Day/Year)

130 WAVERLY STREET

(Street)

(Check all applicable)

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_\_ 10% Owner

CAMBRIDGE. MAÂ 02139

(State)

Officer Other (give title below) (specify below)

\_X\_ Form filed by One Reporting Person Form filed by More than One

Reporting Person

(City)

(Zip)

**Table I - Non-Derivative Securities Beneficially Owned** 

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

3. Ownership 4. Nature of Indirect Beneficial Ownership

(Instr. 4)

Form: Direct (D) or Indirect (Instr. 5)

(I)

(Instr. 5)

Redeemable Preferred Stock 450,000

D

Â

Common Stock

466,680 (1) (2)

Â D

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** 

4. Conversion or Exercise

Ownership Form of

6. Nature of Indirect Beneficial Ownership

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Warrants	09/26/2001	02/01/2009	Common Stock	1,962,494 (1)	\$ 5.64	D	Â
Series A Prefered Stock	09/26/2001	01/31/2006(3)	Common Stock	381,596 <u>(1)</u>	\$ 5.73	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
VERTEX PHARMACEUTICALS INC / MA 130 WAVERLY STREET CAMBRIDGE, MA 02139	Â	ÂX	Â	Â	

# **Signatures**

Kenneth S. Boger, Attorney-In-Fact

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) After taking into account a 1:2.293 reverse stock split of the Issuer's Common Stock and, in the case of Warrants and the Series A Preferred Stock, adjustments to the applicable exercise price or conversion price, respectively, as a result of such reverse stock split.
- (2) Includes 30,528 (post-split) shares held by Joshua S. Boger, the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated, for which Vertex disclaims beneficial ownership.
- (3) Reflecting the anticipated date of the closing of the Issuer's initial public offering of common stock, upon which the Series A Preferred Stock will convert into the indicated number of shares of Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2